BACKGROUND: A role for CXCR3, the receptor for chemokines Mig, IP-10 and interferon-inducible T cell alpha-chemoattractant, in tumour cell migration during melanoma progression has been proposed. AIMS: To analyse CXCR3 expression in primary cutaneous malignant melanomas and its comparison with clinicopathological and prognostic factors. METHODS: A retrospective immunohistochemical study was carried out on formalin-fixed paraffin-wax-embedded sections from 82 patients with primary invasive cutaneous melanomas, with a monoclonal antibody to CXCR3 (clone 49801.111; R&D Systems). Immunoreactivity was semiquantitatively evaluated: labelling intensity (0, absent; 1, weak; 2, moderate; 3, strong) multiplied by the percentage of cells in each of the four intensity categories. A positive staining was considered when the score was >100. Melanomas were categorised by age, sex, primary site, tumour thickness, growth phase, ulceration, lymphocytic infiltration, recurrence, lymph node and distant metastasis, and survival. Univariate and multivariate statistical analyses were carried out. RESULTS: Of the 82 patients, a positive CXCR3 staining was found in 26 (31.7%) patients, whereas 56 (68.3%) were negative. In univariate analysis, a significant association of CXCR3-positive tumour cell immunostaining with tumour thickness >1 mm (p = 0.003), absence of lymphocytic infiltration (p = 0.04) and the presence of distant metastasis (p = 0.048) was found. Multivariate analysis found tumour thickness as the only independent factor with considerable association with distant metastases. CONCLUSIONS: Our findings of a positive correlation of CXCR3 tumour cell immunoreactivity in human primary cutaneous melanoma with tumour thickness >1 mm and absence of intratumoral lymphocytic infiltration support the biological implication of CXCR3 in the tumour progression of cutaneous malignant melanoma.
BACKGROUND: A role for CXCR3, the receptor for chemokines Mig, IP-10 and interferon-inducible T cell alpha-chemoattractant, in tumour cell migration during melanoma progression has been proposed. AIMS: To analyse CXCR3 expression in primary cutaneous malignant melanomas and its comparison with clinicopathological and prognostic factors. METHODS: A retrospective immunohistochemical study was carried out on formalin-fixed paraffin-wax-embedded sections from 82 patients with primary invasive cutaneous melanomas, with a monoclonal antibody to CXCR3 (clone 49801.111; R&D Systems). Immunoreactivity was semiquantitatively evaluated: labelling intensity (0, absent; 1, weak; 2, moderate; 3, strong) multiplied by the percentage of cells in each of the four intensity categories. A positive staining was considered when the score was >100. Melanomas were categorised by age, sex, primary site, tumour thickness, growth phase, ulceration, lymphocytic infiltration, recurrence, lymph node and distant metastasis, and survival. Univariate and multivariate statistical analyses were carried out. RESULTS: Of the 82 patients, a positive CXCR3 staining was found in 26 (31.7%) patients, whereas 56 (68.3%) were negative. In univariate analysis, a significant association of CXCR3-positive tumour cell immunostaining with tumour thickness >1 mm (p = 0.003), absence of lymphocytic infiltration (p = 0.04) and the presence of distant metastasis (p = 0.048) was found. Multivariate analysis found tumour thickness as the only independent factor with considerable association with distant metastases. CONCLUSIONS: Our findings of a positive correlation of CXCR3tumour cell immunoreactivity in human primary cutaneous melanoma with tumour thickness >1 mm and absence of intratumoral lymphocytic infiltration support the biological implication of CXCR3 in the tumour progression of cutaneous malignant melanoma.
Authors: M M Robledo; R A Bartolome; N Longo; J M Rodríguez-Frade; M Mellado; I Longo; G N van Muijen; P Sánchez-Mateos; J Teixidó Journal: J Biol Chem Date: 2001-09-24 Impact factor: 5.157
Authors: Marina Saetta; Margherita Mariani; Paola Panina-Bordignon; Graziella Turato; Cecilia Buonsanti; Simonetta Baraldo; Cinzia M Bellettato; Alberto Papi; Lorenzo Corbetta; Renzo Zuin; Francesco Sinigaglia; Leonardo M Fabbri Journal: Am J Respir Crit Care Med Date: 2002-05-15 Impact factor: 21.405
Authors: A Müller; B Homey; H Soto; N Ge; D Catron; M E Buchanan; T McClanahan; E Murphy; W Yuan; S N Wagner; J L Barrera; A Mohar; E Verástegui; A Zlotnik Journal: Nature Date: 2001-03-01 Impact factor: 49.962
Authors: C Agostini; F Calabrese; F Rea; M Facco; A Tosoni; M Loy; G Binotto; M Valente; L Trentin; G Semenzato Journal: Am J Pathol Date: 2001-05 Impact factor: 4.307
Authors: Nathaniel H Fleming; Judy Zhong; Inês Pires da Silva; Eleazar Vega-Saenz de Miera; Bobbi Brady; Sung Won Han; Doug Hanniford; Jinhua Wang; Richard L Shapiro; Eva Hernando; Iman Osman Journal: Cancer Date: 2014-08-25 Impact factor: 6.860
Authors: Frederick Allen; Iuliana D Bobanga; Peter Rauhe; Deborah Barkauskas; Nathan Teich; Caryn Tong; Jay Myers; Alex Y Huang Journal: Oncoimmunology Date: 2017-11-20 Impact factor: 8.110
Authors: Helena Harlin; Yuru Meng; Amy C Peterson; Yuanyuan Zha; Maria Tretiakova; Craig Slingluff; Mark McKee; Thomas F Gajewski Journal: Cancer Res Date: 2009-03-17 Impact factor: 12.701
Authors: Thomas Dittmar; Christoph Heyder; Eva Gloria-Maercker; Wolfgang Hatzmann; Kurt S Zänker Journal: Clin Exp Metastasis Date: 2007-09-08 Impact factor: 5.150